News|Articles|December 6, 2024

Antibiotic Selection but not Treatment Duration Follows Guidelines for Community Acquired Pneumonia

Study finds antibiotic selection generally follows CAP guidelines but identifies determinants of frequently longer treatment durations.

Adherence to in-patient treatment guidelines for community-acquired pneumonia (CAP) was higher for antibiotic choice than for duration of treatment, in a study in Norway that found elevated C-reactive protein (CRP) was one factor associated with longer treatment durations.1

"This finding suggests that clinicians may prioritize laboratory results, such as CRP levels, over the patient's clinical condition when determining the duration of antibiotic therapy," remarked lead author Dagfinn Markussen, PhD Candidate, University of Bergen, Bergen, Norway, and colleagues.

"This emphasis on inflammatory markers could lead to prolonged antibiotic use, even when the patient's clinical status may not warrant it," the investigators cautioned.

Markussen and colleagues sought to identify patient factors that might contribute to physicians adhering to or varying from treatment guidelines for inpatients admitted with diagnosis of CAP. The study consisted of two cohorts with identical inclusion and exclusion criteria drawn from a randomized controlled trial (that had investigated rapid syndromic testing) and additional, prospectively identified patients.

What You Need to Know

While adherence to antibiotic selection guidelines for community-acquired pneumonia (CAP) was high (80%), 79.8% of patients received antibiotic treatment durations longer than recommended. For patients with a CRB-65 score of ≤2, where guidelines recommend 5 days, the median duration was 7.8 days.

Elevated C-reactive protein (CRP) levels and hospital stays exceeding 2 days were major factors linked to extended antibiotic durations.

A significant portion of prolonged antibiotic use occurred post-discharge, highlighting the need to optimize discharge practices as part of antimicrobial stewardship programs.

"This approach allowed for a more robust analysis by including a larger patient population, facilitating a comprehensive evaluation of guideline adherence over time," Markussen told Contagion.

A total of 479 patients were included in the analysis of empirical antibiotic treatment, and 341 in the treatment duration analysis. Among the exclusion criteria was clinical instability at day 5 or 7 of antibiotic treatment; with stability defined as afebrile, respiratory rate of ≤24/minute, peripheral oxygen saturation >90% on ambient air, and ability to eat.

Norwegian guidelines for inpatient treatment of CAP recommend total antibiotic duration of 5 days for clinically stable patients with mild to moderate symptoms, corresponding to CRB-65 score of 0-2; and 7 days for more severe symptoms.

Markussen and colleagues reported that antibiotic selection largely conformed to guideline recommendation, with 80 % of antibiotics consistent with guidelines. Factors associated with variance from the recommended antibiotic were antibiotic allergy, prior antibiotic treatment within the month before admission, and a high CRB-65 score.

Treatment duration, however, exceeded guideline recommendation in 79.8% of the cohort included in analysis.The median antibiotic duration for all patients in the analysis was 7.9 days, with 19.6% exceeding 10 days.For those with a CRB-65 score of ≤2, where guidelines recommend 5 days, the median was 7.8 days.The median duration of in-hospital antibiotic treatment was 2.9 days, and 5 days in post-discharge treatment.

"We ...want to stress the importance of optimizing discharge practices within stewardship programs, as post-discharge prescriptions account for a large proportion of the total treatment duration," the investigators indicated.

The principle factors associated with treatment durations exceeding recommendation included an elevated CRP level, and length of stay exceeding 2 days.The detection of Gram-negative bacteria was also associated with longer treatment durations.

"The prolonged treatment in these cases (of Gram-negative bacteria) may be warranted, as the empirical regimens might not adequately cover these bacteria," the investigators acknowledged."However, it is important to note that the presence of bacteria, especially when detected from non-sterile body sites such as the airway, does not always indicate an active infection.

Markussen pointed out that their findings are not necessarily able to be generalized to other settings."Norway's success in maintaining low antibiotic use and resistance is largely attributed to comprehensive stewardship strategies implemented at both national and institutional levels.Healthcare institutions receive regular feedback on antibiotic prescriptions, including broad-spectrum antibiotic usage, with national averages serving as benchmarks."

"Previous studies, including ours, have shown that the success of these interventions is highly dependent on their implementation and context," Markussen said. "Engaging stakeholders is essential for designing and executing effective stewardship interventions."

Reference
1. Markussen DL, Wathne JS, Ritz C, et al. Determinants of non-adherence to antibiotic treatment guidelines in ospitalized adults with suspected ocmmunity-acquired pneumonia: A prospective study. Antimicrob Resist Infect Control 2024 Nov 23; 13:140. doi:10.1186/s13756-024-01494-2. Accessed December 2, 2024.

Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Measles Update: October 16, 2026
The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.